SCHEMBL1889244

SCHEMBL1889244

Br[Mg]c1ccc(-c2ccc(Br)s2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
KDM4E B2RXH2 4/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
RXFP1 Q9HBX9 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 2/20 0.39
PPARG P37231 2/20 0.39
NCOA2 Q15596 2/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
NCOA1 Q15788 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
SNCA P37840 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
ALOX12 P18054 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5056568 0.85
SCHEMBL197157 0.80 SNCA (0.50) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL5453288 0.77 SNCA (0.48) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL5889177 0.77 SNCA (0.48) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL498474 0.77 SNCA (0.48) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL5889194 0.77 SNCA (0.48) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL7045583 0.74
SCHEMBL196515 0.73 LTA4H (0.52) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL498603 0.71 DPP4 (0.53) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL16140274 0.70 SNCA (0.43) MAPTKDM4ERAB9ASMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110101318-A1 NOVEL MACROMOLECULAR COMPOUNDS HAVING A CORE-SHELL STRUCTURE FOR USE AS SEMICONDUCTORS HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110101318-A1 NOVEL MACROMOLECULAR COMPOUNDS HAVING A CORE-SHELL STRUCTURE FOR USE AS SEMICONDUCTORS EPCAM, MRPS22, ILK MAPT 454/4885KDM4E 3316/4885RAB9A 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.